Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy?

Saudi Journal of Gastroenterology

Volumn 19, Issue 3, 2013, Pages 113-120

  Dajani, Asad I ^a   Abu Hammour, Adnan M ^b   Yang, Ding H ^c   Chung, Peter C ^d   Nounou, Mohammed A ^e   Yuan, Kaitao Y ^f   Zakaria, Mohammed A ^g   Schi, Hanping S ^f  

^a ADSC   (United Arab Emirates)

^b Dubai   (United Arab Emirates)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d 9th People's Hospital   (China)

^e MNC Sharjah ^*  (United Arab Emirates)

^f SUN YAT SEN UNIVERSITY   (China)

^g HMC   (United Arab Emirates)

Author keywords

B. infantis; Helicobacter pylori; probiotics; sequential therapy; triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR;

ADJUVANT THERAPY; ADOLESCENT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BIFIDOBACTERIUM LONGUM INFANTIS; CHILD; CHRONIC GASTRITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; ULCER;

ADOLESCENT; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; CLARITHROMYCIN; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROBIOTICS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878618035     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.111953     Document Type: Article

References (27)

1. Dajani AI, Awad S, Ukabam S, Nounou MA, Abdul Rasheed Z, Gautam S, et al. One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. Digestion 1999;60:298-304. (Pubitemid 29221899)
2. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25. (Pubitemid 47206706)
3. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
4. Abou Hammour A, Dajani AI, Nounou M, Zakaria M, Mohammed N, Al Badri S. Current stand of classical triple therapy for the eradication of H. pylori in the UAE. Proceedings of the 6 th Emirates Gastroenterology and Hepatology Conference, oral presentation in H. pylori plenary session April, 2010.
5. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 2007;146:556-63. (Pubitemid 351650536)
6. Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31. (Pubitemid 351860824)
7. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22:360-6. (Pubitemid 37163724)
8. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68. (Pubitemid 46046372)
9. Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003;18:805-13. (Pubitemid 37323646)
10. Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, et al. Pretreatment with Lactobacillus-and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr 2006;83:864-9.
11. Deguchi R, Nakaminami H, Rimbara E, Noguchi N, Sasatsu M, Suzuki T, et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 2012;27:888-92.
12. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90. (Pubitemid 43980633)
13. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Helicobacter 1996;1:138-44. (Pubitemid 126671139)
14. Adamek RJ, Szymanski C, Pfaffenbach B, Opferkuch W, Ricken D, Wegener M. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection. Dtsch Med Wochenschr 1995;120:358-60.
15. Labenz J, Peitz U, Tillenburg B, Becker T, Börsch G, Stolte M. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori Leber Magen Darm 1995;25:122.
16. Prazeres Magalhães P, De Magalhães Queiroz DM, Campos Barbosa DV, Aguiar Rocha G, Nogueira Mendes E, Santos A, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002;46:2021-3. (Pubitemid 34535237)
17. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006;28:6-13.
18. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10:1088-94. (Pubitemid 38697703)
19. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 2010;25:S75-9.
20. Kuwayama H, Asaka M, Sugiyama T, Fukuda Y, Aoyama N, Hirai Y, et al. Rabeprazole-based eradication therapy for Helicobacter pylori: A large-scale study in Japan. Aliment Pharmacol Ther 2007;25:1105-13. (Pubitemid 46587695)
21. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007;137:812S-8.
22. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012;46:468-81.
23. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004;20:1181-8. (Pubitemid 39657952)
24. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: The role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011;45:960-6.
25. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9. (Pubitemid 35265423)
26. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008;295:G1025-34.
27. Yuan KT. PhD Thesis., Guangzhou, China: Department of Surgery, First Affliated Hospital of Sun Yat-Sen University; 2012. p. 42-58